Stada Partners With Calliditas On Novel Budesonide Formulation
Deal Worth Over $100m Targets First European Approval For Orphan IgAN Treatment
Stada has struck a licensing and commercialization deal with Calliditas worth more than $100m to partner on a novel oral formulation of budesonide to treat Immunoglobulin A Nephropathy in Europe.
